Leiomyosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal or soft tissue origin. Symptoms include a noticeable lump or swelling, pain, if it presses on nerves or muscles and a blockage in the stomach or intestines or gastrointestinal bleeding if the tumor is located in the abdomen or digestive tract. Predisposing factors include age, chemical exposure and radiation exposure.

The Leiomyosarcoma – drugs in development research report provides a comprehensive overview on the therapeutics under development for Leiomyosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Leiomyosarcoma and features dormant and discontinued projects.

Key Targets in the Leiomyosarcoma Pipeline Drugs Market

In the Leiomyosarcoma pipeline drugs market the key targets are Vascular Endothelial Growth Factor Receptor 2, Programmed Cell Death 1 Ligand 1, Programmed Cell Death Protein 1, Vascular Endothelial Growth Factor Receptor 3, Mast/Stem Cell Growth Factor Receptor Kit, Cells Expressing Ganglioside GD2, Cells Expressing Latent Membrane Protein 1, Cells Expressing Latent Membrane Protein 2, Exportin 1, Fibroblast Growth Factor Receptor, Leukocyte Surface Antigen CD47, Platelet Derived Growth Factor Receptor Beta. Vascular Endothelial Growth Factor Receptor 2 has the highest number of pipeline products.

Leiomyosarcoma Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the Leiomyosarcoma Pipeline Drugs Market

Vascular Endothelial Growth Factor Receptor 2 Inhibitor has the highest number of pipeline products followed by Programmed Cell Death 1 Ligand 1 Inhibitor, Programmed Cell Death Protein 1 Antagonist, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Cytotoxic To Cells Expressing Ganglioside GD2, Cytotoxic To Cells Expressing Latent Membrane Protein 1 , Cytotoxic To Cells Expressing Latent Membrane, Protein 2, Exportin 1 Inhibitor, and Fibroblast Growth Factor Receptor Inhibitor.

Leiomyosarcoma Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

Leiomyosarcoma Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Leiomyosarcoma pipeline drugs market are Intravenous, Oral, Subcutaneous, Intratumor, Intravenous Drip, Intravesical, Parenteral, Topical, Intradermal, and Intralesional. Intravenous has the maximum number of pipeline products.

Leiomyosarcoma Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Leiomyosarcoma Pipeline Drugs Market

In the Leiomyosarcoma pipeline drugs market the key molecule types are Small Molecule, Monoclonal Antibody, Cell Therapy, Fusion Protein, Biologic, Gene-Modified Cell Therapy, Inactivated Vaccine, Monoclonal Antibody Conjugated, and Recombinant Peptide.

Leiomyosarcoma Pipeline Drugs Market, by Molecule Types

To get more insights on key molecule types, download a free sample report

Major Companies in the Leiomyosarcoma Pipeline Drugs Market

The major companies in the Leiomyosarcoma pipeline drugs market are Advenchen Laboratories LLC, AstraZeneca Plc, Pharma Mar SA, Karyopharm Therapeutics Inc, Merck KGaA, Pfizer Inc, 3SBio Inc, Actuate Therapeutics Inc, Agenus Inc, Alphamab Oncology, ALX Oncology Holdings Inc, Apexigen Inc, and APIM Therapeutics AS.

Leiomyosarcoma Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Leiomyosarcoma Pipeline Drugs Market Overview

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Leiomyosarcoma
• The pipeline guide reviews pipeline therapeutics for Leiomyosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Leiomyosarcoma therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Leiomyosarcoma therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for Leiomyosarcoma

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Leiomyosarcoma
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Leiomyosarcoma pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.